Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
Open Access
- 28 August 2014
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 124 (9), 1426-1433
- https://doi.org/10.1182/blood-2014-03-560557
Abstract
Key Points Volasertib plus low-dose cytarabine increased the response rate and improved survival in AML patients ineligible for intensive treatment. Volasertib plus low-dose cytarabine resulted in responses across all AML genetic subgroups and had a clinically manageable safety profile.Keywords
This publication has 33 references indexed in Scilit:
- Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survivalBlood, 2013
- NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic MalignanciesMolecular Cancer Therapeutics, 2012
- TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing RegimensMolecular Cancer Therapeutics, 2012
- TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcomeBlood, 2012
- A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or olderBlood, 2009
- Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cellsBlood, 2009
- BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In VivoCurrent Biology, 2007
- Two‐stage adaptive strategy for superiority and non‐inferiority hypotheses in active controlled clinical trialsStatistics in Medicine, 2004
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958